Last reviewed · How we verify
NCT03623854
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
Completed
Phase 2
Last updated 16 April 2024
What this trial tests
Phase 2 trial testing Nivolumab in Chordoma in 10 participants. Completed in 28 September 2023.
Timeline
3 April 2019
Primary endpoint
28 September 2023
28 September 2023
28 September 2023
Quick facts
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 3 April 2019 |
| Primary completion | 28 September 2023 |
| Estimated completion | 28 September 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Nivolumab (nivolumab) — full drug profile →
- Relatlimab — full drug profile →
Conditions studied
- Chordoma — all drugs for Chordoma →
- Locally Advanced Chordoma — all drugs for Locally Advanced Chordoma →
- Metastatic Chordoma — all drugs for Metastatic Chordoma →
- Unresectable Chordoma — all drugs for Unresectable Chordoma →
Sponsor
Jonsson Comprehensive Cancer Center — full company profile →
Who can join
12 and older, any sex, with Chordoma or Locally Advanced Chordoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body. Monoclonal antibodies, such as nivolumab and relatlimab, may interfere with the ability of tumor cells to grow and spread.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S, Xu L, Yi M, Yu S, et al · · 2019 · cited 909× · PMID 31690319 · DOI 10.1186/s12943-019-1091-2 -
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.
Li C, Jiang P, Wei S, Xu X, et al · · 2020 · cited 679× · PMID 32680511 · DOI 10.1186/s12943-020-01234-1 -
NK Cell-Based Immune Checkpoint Inhibition.
Khan M, Arooj S, Wang H. · · 2020 · cited 296× · PMID 32117298 · DOI 10.3389/fimmu.2020.00167 -
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y, Zhang H, Liu C, Wang Z, et al · · 2022 · cited 179× · PMID 35978433 · DOI 10.1186/s13045-022-01325-0 -
Understanding LAG-3 Signaling.
Chocarro L, Blanco E, Zuazo M, Arasanz H, et al · · 2021 · cited 154× · PMID 34067904 · DOI 10.3390/ijms22105282 -
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y, Wang X, Jin T, Tian Y, et al · · 2020 · cited 133× · PMID 33122640 · DOI 10.1038/s41392-020-00348-8 -
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application.
Huo JL, Wang YT, Fu WJ, Lu N, et al · · 2022 · cited 124× · PMID 35958563 · DOI 10.3389/fimmu.2022.956090 -
Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C, Hu Y, Shi C. · · 2020 · cited 91× · PMID 32140153 · DOI 10.3389/fimmu.2020.00060
Verify or expand the search:
- PubMed search for NCT03623854
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nivolumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
- NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting
Other recruiting trials for Chordoma
Currently open trials in the same condition.
- NCT06029218 — Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy · NA · recruiting
- NCT05407441 — Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · Phase 1, PHASE2 · active not recruiting
- NCT05861245 — Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base · NA · recruiting
- NCT05041127 — Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma · Phase 2 · active not recruiting
- NCT05033288 — Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone · recruiting
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
- NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03623854 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
- Last refreshed: 16 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03623854.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing